Laurence Kessler

Prof. Laurence Kessler


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
BMBastien Misgault
Bastien Misgault
ECEva Chatron
Eva Chatron
QRQuitterie Reynaud
Quitterie Reynaud
STSandrine Touzet
Sandrine Touzet
MAMichel Abely
Michel Abely
LKLaurence Kessler
Laurence Kessler

23 May 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
GFGuy Fagherazzi
Guy Fagherazzi
GAGloria Aguayo
Gloria Aguayo
LZLu Zhang
Lu Zhang
HHHélène Hanaire
Hélène Hanaire
SPSylvie Picard
Sylvie Picard
JRJean-Pierre Riveline
Jean-Pierre Riveline
Aims/hypothesis: Our study aims to uncover glycaemic phenotype heterogeneity in type 1 diabetes. Methods: In the Study of the French-speaking Society of Type 1 Diabetes (SFDT1), we characterised glycaemic heterogeneity thanks to a set of complementary metrics: HbA1c, time in range (TIR), time below range (TBR), CV, Gold score and glycaemia risk index (GRI). Applying the Discriminative Dimensionality Reduction with Trees (DDRTree) algorithm, we created a phenotypic tree, i.e. a 2D visual mapping. We also carried out a clustering analysis for comparison. Results: We included 618 participants with type 1 diabetes (52.9% men, mean age 40.6 years [SD 14.1]). Our phenotypic tree identified seven glycaemic phenotypes. The 2D phenotypic tree comprised a main branch in the proximal region and glycaemic phenotypes in the distal areas. Dimension 1, the horizontal dimension, was positively associated with GRI (coefficient [95% CI]) (0.54 [0.52, 0.57]), HbA1c (0.39 [0.35, 0.42]), CV (0.24 [0.19, 0.28]) and TBR (0.11 [0.06, 0.15]), and negatively with TIR (−0.52 [−0.54, −0.49]). The vertical dimension was positively associated with TBR (0.41 [0.38, 0.44]), CV (0.40 [0.37, 0.43]), TIR (0.16 [0.12, 0.20]), Gold score (0.10 [0.06, 0.15]) and GRI (0.06 [0.02, 0.11]), and negatively with HbA1c (−0.21 [−0.25, −0.17]). Notably, socioeconomic factors, cardiovascular risk indicators, retinopathy and treatment strategy were significant determinants of glycaemic phenotype diversity. The phenotypic tree enabled more granularity than traditional clustering in revealing clinically relevant subgroups of people with type 1 diabetes. Conclusions/interpretation: Our study advances the current understanding of the complex glycaemic profile in people with type 1 diabetes and suggests that strategies based on isolated glycaemic metrics might not capture the complexity of the glycaemic phenotypes in real life. Relying on these phenotypes could improve patient stratification in type 1 diabetes care and personalise disease management. Graphical

28 October 2024 in Cells
Verified
Journal Article
Open access
PDF file
ALALLAN LANGLOIS
ALLAN LANGLOIS
MPMichel Pinget
Michel Pinget
LKLaurence Kessler
Laurence Kessler
KBKarim Bouzakri
Karim Bouzakri
Islet transplantation is a promising approach for treating patients with unstable T1DM. However, it is confronted with numerous obstacles throughout the various stages of the transplantation procedure. Significant progress has been made over the last 25 years in understanding the mechanisms behind the loss of functional islet mass and in developing protective strategies. Nevertheless, at present, two to three pancreases are still needed to treat a single patient, which limits the maximal number of patients who can benefit from islet transplantation. Thus, this publication provides an overview of recent scientific findings on the various issues affecting islet transplantation. Specifically, we will focus on the understanding of the mechanisms involved and the strategies developed to alleviate these problems from the isolation stage to the post-transplantation phase. Finally, we hope that this review will highlight new avenues of action, enabling us to propose pancreatic islet transplantation to a maximum number of patients with T1DM.

4 March 2021 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
PDF file
CDClémentine Dillmann
Clémentine Dillmann
LALamia Amoura
Lamia Amoura
FMFatéma Fall Mostaine
Fatéma Fall Mostaine
ACAdrien Coste
Adrien Coste
LBLeila Bounyar
Leila Bounyar
LKLaurence Kessler
Laurence Kessler
Hospitalization of persons with diabetes in an inpatient diabetes unit is challenging, notably for patients having different profiles. We aimed to evaluate the feasibility and the benefit of a continuous glucose monitoring (CGM) telemetry system to control glucose excursions in hospitalized patients with diabetes, according to their diabetes type and the reasons for their hospitalization. A prospective pilot study was conducted in 53 insulin-requiring diabetes patients hospitalized in the general ward. Glucose was monitored using Guardian Connect (GC, Medtronic) to adopt insulin therapy. The time in range (TIR, target 70-180 mg/dL), the time below range (TBR), and the time above range (TAR) were recorded by GC between the start of hospitalization (SH) and end of hospitalization (EH), and analyzed according to the diabetes type (type 1 diabetes n = 28, type 2 diabetes n = 25) and the reasons for hospitalization (acute complications n = 35, therapeutic education n = 18). Patient and caregiver satisfaction was also assessed. In patients with type 2 diabetes and those hospitalized for acute complications, TIR significantly increased between the SH and EH, from 75.7% (95%CI 48.5-84.6) to 82.2% (95%CI 63.2-91.8) P = 0.043 and from 58.3% (95%CI 46.3-69.7) to 66.4% (95%CI 55.6-75.5) P = 0.031, respectively, and TAR significantly decreased, with no change in TBR. In patients with diabetes hospitalized for therapeutic education, TBR significantly decreased from 3.4% (95%CI 0-9.4) to 0% (95%CI 0-3.8) P = 0.037. Finally, 94% of patients and caregivers deemed the GC system useful. CGM telemetry system use is feasible and well accepted in patients hospitalized in diabetes care unit and could be useful to improve therapeutic education and metabolic control, especially for specific homogenous populations with diabetes.

25 June 2010 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LKLaurence Kessler
Laurence Kessler
SBS. Bakopoulou
S. Bakopoulou
RKR. Kessler
R. Kessler
GMG. Massard
G. Massard
NSN. Santelmo
N. Santelmo
OGon behalf of the GRAGIL group
on behalf of the GRAGIL group
Patients with end‐stage cystic fibrosis (CF) and severe CF‐related diabetes (CFRD) may benefit from combined lung‐pancreatic islet transplantation. In the present study, we report the long‐term follow‐up of four end‐stage CF patients treated with combined bilateral lung and pancreatic islet transplantation from the same donor. All patients were C‐peptide negative (0.5 μg/L). At 6 months after transplantation, one patient showed multiple episodes of acute lung transplant rejection and a progressive decline in pancreatic islet cell function. Three out of four patients experienced an improved control of glucose levels with a HbA1c of 5.2%, 7% and 6% respectively at 1.5, 2 and 15 years follow‐up. Compared with the pretransplant period, there was a 50% reduction in mean daily insulin needs. Pulmonary function remained satisfactory in all patients. In conclusion, our cases series shows that combined bilateral lung and pancreatic islet transplantation may be a viable therapeutic option for patients with end‐stage CF and CFRD.

15 February 2012 in Transplantation
Verified
Journal Article
Closed access
FMFrançois Moreau
François Moreau
FTFlorence Toti
Florence Toti
FBFrançois Bayle
François Bayle
TBThierry Berney
Thierry Berney
HEHarald Egelhofer
Harald Egelhofer
LKLaurence Kessler
Laurence Kessler